Careers at the forefront of respiratory health
Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and chronic obstructive pulmonary disease (COPD). Our 40-year heritage in respiratory science is just the beginning of our story.
Today, more than 600 million individuals have asthma or COPD and significant opportunities remain to expand care.
Respiratory is one of AstraZeneca’s three main therapy areas. In 2017, our respiratory medicines reached more than 18 million patients. We have a strong pipeline with more than 33,000 patients participating in Phase I-IV respiratory clinical trials across the world.
If you’re inspired by the possibilities of what science can do for people living with severe asthma and COPD, click below to see our current open roles.
AstraZeneca’s respiratory biologics portfolio – a growing opportunity
Respiratory biologics is a key focus for AstraZeneca, and we are expanding our team with a number of exciting opportunities. Currently, our respiratory biologics portfolio includes one recently approved medicine for the treatment of severe eosinophilic asthma, with numerous regulatory decisions pending in additional countries across the globe. As the first-launched respiratory biologic for AstraZeneca, this medicine is a top priority for our company.
We are now pursuing this medicine’s potential to improve patient outcomes and reframe patient care in other eosinophil-driven diseases that cause debilitating symptoms for patients and dramatically decrease their quality of life.
Looking to the future, our late-stage biologics pipeline includes tezepelumab, a monoclonal antibody under investigation for the treatment of severe asthma, that has received breakthrough therapy designation from the US Food and Drug Administration.
Who we look for
To achieve our ambition, we are currently recruiting talented, passionate individuals to join our BioPharmaceuticals R&D unit and BioPharmaceuticals Commercial unit to help us accelerate our work and bring our medicines to as many patients as possible.
AZ BioPharmaceuticals R&D team
In BioPharmaceuticals R&D, the team’s mission is to transform innovative molecules into medicines that change lives.
The new R&D BioPharmaceuticals organisation brings together research and development teams, from discovery through to late-stage development for Cardiovascular, Renal & Metabolic (CVRM), Respiratory, Inflammatory and Autoimmune (RIA) therapy areas, and opportunistically for Microbial Sciences and Neuroscience.
For our respiratory biologics, the BioPharmaceuticals R&D team helps define new life-cycle opportunities, including new indications we may pursue for our medicines, and design and deliver new studies that provide the data for regulatory submissions around the world.
AZ BioPharmaceuticals Commercial team
The BioPharmaceuticals Commercial team creates and executes winning therapeutic area and product strategies that change the practice of medicine for the benefit of patients and shape the future of AstraZeneca. BioPharmaceuticals Commercial integrates global marketing, corporate and medical affairs functions to drive scientific development and commercial excellence in the core areas of cardiovascular and respiratory diseases.
For our respiratory biologics, BioPharmaceuticals Commercial works to develop global strategy for brands through insight gathering and analytics to support flawless execution in partnership with our country-level teams.
Why join AstraZeneca Respiratory
If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.
At AstraZeneca, we transform ideas into life-changing medicine. That difference starts with you. As one of Science Magazine’s 2017 Top Employers, we need people like you who share our passion for science and determination to meet patients’ needs around the world.
If you’re confident to lead, willing to collaborate and curious about what science can do, then you’re our kind of person.
